Seraph Closes $4.2 Million Series B

Seraph Closes $4.2 Million Series B Round


DETROIT, April 28, 2019 – Seraph Biosciences, Inc., creator of Seraspec®, is pleased to announced that it has just closed a $4.2 million Series B Financing Round.

Almost immediately following the addition of Dr. Gary Loveman to its Board of Directors this past February, Seraph raised the intermediate round from a syndicate of private investors. “This investment will allow us to continue commercialization efforts with our veterinary partner while steadily progressing toward an FDA clinical trial for human use.” said Seraph CEO Jim Shanley, “we are excited about the momentum this creates for our company and Detroit’s entrepreneurial community”.

About Seraph Biosciences, Inc.

Incorporated in 2016, Seraph Biosciences, Inc. is a biotechnology company dedicated to commercializing Seraspec® – a fully automated pathogen identification platform capable of delivering near real-time pathogen detection. Based in Detroit, Michigan, Seraph’s mission is to provide disruptive biomedical solutions to front-line providers and their patients at the point of care.